Piramal Pharma Limited reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported sales was INR 19,585.7 million compared to INR 17,159.7 million a year ago. Revenue was INR 20,200.8 million compared to INR 17,985.1 million a year ago. Net income was INR 101.1 million compared to net loss of INR 901.8 million a year ago. Basic earnings per share from continuing operations was INR 0.08 compared to basic loss per share from continuing operations of INR 0.74 a year ago. Diluted earnings per share from continuing operations was INR 0.08 compared to diluted loss per share from continuing operations of INR 0.74 a year ago.
For the nine months, sales was INR 56,188 million compared to INR 49,179.7 million a year ago. Revenue was INR 57,678.1 million compared to INR 51,185.8 million a year ago. Net loss was INR 834.5 million compared to INR 2,365.7 million a year ago. Basic loss per share from continuing operations was INR 0.66 compared to INR 1.95 a year ago. Diluted loss per share from continuing operations was INR 0.66 compared to INR 1.95 a year ago.